Shots: The approval follows P-III ORIENT-11 study assessing Tyvyt (sintilimab) vs PBO + Almita (pemetrexed) and platinum CT in 397 participants in a ratio (2:1) as 1L therapy for advanced […]readmore
Tags : pemetrexed
Shots: The expanded label approval is based on P-III KEYNOTE-189 study results assessing Alimta + pembrolizumab + Pt-based CT vs Alimta + Pt-based CT +PBO in 616 patients with mnon-sq […]readmore